Soft-tissue sarcoma (STS) is a rare mesenchymal tumor for which therapies are limited. Preclinical evidence has suggested that targeting MET and VEGF may be a therapeutic strategy in STS. To this end, Coyne and colleagues conducted a phase II clinical trial of single-agent cabozantinib, which targets both MET and VEGF signaling, in patients with advanced STS having progressed on prior systemic therapy. Although 11.1% of patients experienced objective responses, and the 6-month PFS was 49.3%, this study did not meet its primary endpoint. However, responses were observed in multiple subtypes of STS, suggesting that similar trials including multiple STS subtypes may be useful, given the rarity of this tumor type. Furthermore, additional clinical study of cabozantinib is warranted in STS to further refine patients who may benefit from this treatment.

HR-positive/HER2-negative breast cancer is considered to be an immunologically cold tumor type. However, the utility of immunotherapy in this setting...

You do not currently have access to this content.